A recent report from the London Drugs Commission, led by Lord Charlie Falconer QC, recommends that cannabis possession for personal use should no longer be treated as a criminal offense. This report, which was eagerly anticipated, emphasizes the need for reform in UK drug policy and highlights the disproportionate impact of current laws on ethnic minorities in London.
Established by Mayor Sadiq Khan almost three years ago, the London Drugs Commission was tasked with reviewing the effectiveness of existing drug laws, particularly regarding cannabis. The final report, titled ‘The Cannabis Conundrum’, argues that the current approach to cannabis prohibition is excessively punitive and fails to address the real harms associated with its use.
The report contains 42 recommendations, which include decriminalizing cannabis possession and banning the controversial ‘stop and search’ practices that disproportionately target minority communities. Khan has publicly supported the findings, which have already ignited discussions in various media outlets, especially in light of ongoing government reforms in the prison and sentencing systems.
In 2024, the Ministry of Justice reported that the number of people dealt with by the Criminal Justice System in England and Wales rose by 4% to 1.52 million. Out-of-court disposals for minor offenses, including cannabis possession, increased by 5%. Despite this rise, the use of cannabis warnings dropped by 68%, and penalty notices for disorder fell by 44%. Notably, 37% of the 4,100 penalty notices issued were for cannabis possession, resulting in around 1,500 individuals receiving fines on the spot.
The report critiques the severity of penalties for cannabis-related offenses, particularly possession, stating that current punishments are disproportionately high. It highlights that Black Londoners are more likely to be subjected to stop and search yet are no more likely to carry cannabis than other demographic groups. The report calls for an end to this practice, asserting that it leads to long-lasting negative consequences for affected individuals.
While advocating for decriminalization, the report does not support full legalization of cannabis, citing concerns that it may not effectively resolve the issues stemming from prohibition. The authors examined various jurisdictions, including the US and Canada, and concluded that legalization has not eradicated the illicit market and has sometimes replaced one problematic industry with another.
The core recommendation of the report is to reclassify cannabis from the Misuse of Drugs Act 1971 to the Psychoactive Substances Act 2016. This change would allow for the decriminalization of possession while maintaining criminal penalties for distribution and cultivation. Under this new framework, police would lose the authority to conduct stop and search solely based on suspicion of cannabis possession.
Furthermore, the report suggests that this reclassification would protect individuals who use cannabis for medical reasons but cannot afford private prescriptions. It proposes retroactive protections for those previously convicted of cannabis possession.
Other recommendations include improving data collection on cannabis use across different ethnic groups, establishing a drug testing service in London, and exploring the use of prescription-grade cannabis for treating various conditions. Additionally, it calls for enhanced training for police on medical cannabis laws and the introduction of guidelines for the safe use of cannabis in medical settings.
Mike Morgan-Giles, CEO of the Cannabis Industry Council, expressed support for the report’s findings, stating that the current system disproportionately affects ethnic minorities and requires urgent reform.
Dr. Simon Erridge from Curaleaf Clinic emphasized the need to remove barriers to accessing regulated medical cannabis, arguing that current classifications impede patients from receiving necessary care.
Despite the report’s comprehensive recommendations, a Home Office spokesperson indicated that the government does not plan to reclassify cannabis from its current status as a Class B substance under the Misuse of Drugs Act. As discussions continue, the report’s findings are expected to shape the future landscape of cannabis policy in the UK.
English 
Spanish 
German 
Czech